← All trials
NCT01068509
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2010
- Primary completion
- Aug 1, 2013
- Completion date
- Apr 1, 2015
- First posted
- —
- Last posted
- —
- Enrollment
- 63
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- Immutep S.A.Lead sponsor
- University of WashingtonOverall official - principal investigator
- Stanford UniversityOverall official - principal investigator
- Duke UniversityOverall official - principal investigator
- University of California, San FranciscoOverall official - principal investigator
- University of AdelaideOverall official - principal investigator
- Medical University of South CarolinaOverall official - principal investigator
- Marin Cancer CareOverall official - principal investigator
- Indiana UniversityOverall official - principal investigator
- Austin HealthOverall official - principal investigator
- Griffith UniversityOverall official - principal investigator
- University of QueenslandOverall official - principal investigator
- Morristown Memorial HospitalOverall official - principal investigator
- New York Presbyterian HospitalOverall official - principal investigator
- ScrippsOverall official - principal investigator
- University of RochesterOverall official - principal investigator
- Peter MacCallum Cancer CentreOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.